How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Topics: Breast Cancer • Medical Oncology • Triple negative • Residual disease • Breast Cancer, Non-metastatic

Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?

Answer from: Medical Oncologist at Academic Institution

I would treat such a patient the same way that I would any patient with residual TNBC after neoadjuvant chemotherapy and pembrolizumab, which depends to some extent upon the patient's stage at diagnosis and the extent of residual disease at surgery - in patients with residual disease after neoadjuva...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
On a similar note, I just saw a woman post op who ...

Medical Oncologist at Warren Alpert Medical School of Brown University
The low PR expression wouldn't dissuade me from tr...

Related Questions